Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib.
Harvey RD. Clin Pharmacol. 2014 May 8;6:87-96. eCollection 2014.

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
Bringhen S et al. Blood. 2014 May 22. pii: blood-2014-03-563759. [Epub ahead of print].

Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy.
Russell SJ et al. Mayo Clin Proc. 2014 May 12. pii: S0025-6196(14)00332-2. doi: 10.1016/j.mayocp.2014.04.003. [Epub ahead of print].

Randomized, open label, phase 2 study of siltuximab (an anti IL 6 mAb) and bortezomib melphalan prednisone versus bortezomib-melphalan-prednisone in patients with newly diagnosed multiple myeloma.
San Miguel J et al. Blood. 2014 May 15. pii: blood-2013-12-546374. [Epub ahead of print].

Engineering more efficacious antibody therapy for myeloma.
van Rhee F. Blood. 2014 May 15;123(20):3062-3. doi: 10.1182/blood-2014-04-560342.

Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma.
Cai X et al. J Clin Oncol. 2014 May 5. [Epub ahead of print].